{"id":68518,"date":"2026-06-18T22:57:48","date_gmt":"2026-06-18T14:57:48","guid":{"rendered":"https:\/\/flcube.com\/?p=68518"},"modified":"2026-06-18T22:57:50","modified_gmt":"2026-06-18T14:57:50","slug":"gsk-and-spero-therapeutics-secure-fda-approval-for-utebzi-first-oral-carbapenem-antibiotic-for-complicated-utis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68518","title":{"rendered":"GSK and Spero Therapeutics Secure FDA Approval for Utebzi, First Oral Carbapenem Antibiotic for Complicated UTIs"},"content":{"rendered":"\n

GlaxoSmithKline plc (GSK)<\/strong> (NYSE: GSK<\/a>) and Spero Therapeutics<\/strong> (NASDAQ: SPRO<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved Utebzi (tebipenem pivoxil)<\/strong>, the first and only oral carbapenem antibiotic<\/strong> for the treatment of complicated urinary tract infections (cUTIs)<\/strong>, including pyelonephritis, in adult patients with limited or no alternative oral treatment options.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>FDA (United States)<\/td><\/tr>
Approval Type<\/strong><\/td>New Drug Application (NDA) approval<\/td><\/tr>
Product<\/strong><\/td>Utebzi (tebipenem pivoxil) \u2013 oral carbapenem<\/td><\/tr>
Indication<\/strong><\/td>cUTIs including pyelonephritis caused by susceptible pathogens<\/td><\/tr>
Patient Population<\/strong><\/td>Adults with limited\/no alternative oral treatment options<\/td><\/tr>
Approval Date<\/strong><\/td>17 Jun 2026<\/td><\/tr>
Expected US Launch<\/strong><\/td>End of 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 PIVOT-PO Phase 3 Trial<\/h2>\n\n\n\n
Endpoint<\/th>Tebipenem Pivoxil (Oral)<\/th>Imipenem-Cilastatin (IV)<\/th>Result<\/th><\/tr><\/thead>
Overall Success Rate<\/strong><\/td>58.5% (261\/446)<\/td>60.2% (291\/483)<\/td>Non-inferiority demonstrated<\/strong><\/td><\/tr>
Primary Endpoint<\/strong><\/td>Composite of clinical cure + microbiological eradication at test-of-cure<\/td>Same<\/td>Met<\/td><\/tr>
Dosing<\/strong><\/td>600 mg oral<\/td>500 mg intravenous<\/td>Comparable efficacy<\/td><\/tr>
Safety Profile<\/strong><\/td>Generally similar to IV carbapenems<\/td>Standard carbapenem safety<\/td>Favorable tolerability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The pivotal PIVOT-PO phase 3 trial<\/strong> enrolled hospitalized patients with cUTI, including pyelonephritis, and successfully demonstrated that oral tebipenem pivoxil achieved non-inferior efficacy compared to intravenous imipenem-cilastatin, representing a paradigm shift in cUTI management.<\/p>\n\n\n\n

Commercial Partnership Structure<\/h2>\n\n\n\n